logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11851440 B1

PDFFull Text
Date of Patent:
Dec. 26, 2023

Filed:

Nov. 19, 2021

Modulators of eukaryotic initiation factor 2b, compositions and methods

Applicant:

Denali Therapeutics Inc., South San Francisco, CA (US);

Inventors:

Robert A. Craig, II, South San Francisco, CA (US);

Javier de Vicente Fidalgo, Foster City, CA (US);

Anthony A. Estrada, Danville, CA (US);

Jianwen A. Feng, San Mateo, CA (US);

Brian M. Fox, Redwood City, CA (US);

Christopher R. H. Hale, South San Francisco, CA (US);

Katrina W. Lexa, San Francisco, CA (US);

Maksim Osipov, Redwood City, CA (US);

Travis Remarchuk, South San Francisco, CA (US);

Zachary K. Sweeney, Redwood City, CA (US);

Assignee:

Denali Therapeutics Inc., South San Francisco, CA (US);

Attorney:

SHEPPARD MULLIN RICHTER & HAMPTON LLP

Primary Examiner:

Laura L Stockton

Int. Cl.
CPC ...
A61K 31/4245 (2006.01); A61K 31/4164 (2006.01); A61K 31/415 (2006.01); A61K 31/421 (2006.01); C07D 491/048 (2006.01); C07C 235/22 (2006.01); C07D 207/27 (2006.01); C07D 233/36 (2006.01); C07D 233/42 (2006.01); C07D 233/61 (2006.01); C07D 233/64 (2006.01); C07D 249/04 (2006.01); C07D 249/08 (2006.01); C07D 257/04 (2006.01); C07D 261/04 (2006.01); C07D 261/08 (2006.01); C07D 263/32 (2006.01); C07D 263/38 (2006.01); C07D 263/56 (2006.01); C07D 271/06 (2006.01); C07D 271/10 (2006.01); C07D 291/04 (2006.01); C07D 401/12 (2006.01); C07D 403/04 (2006.01); C07D 403/12 (2006.01); C07D 413/04 (2006.01); C07D 413/06 (2006.01); C07D 413/12 (2006.01); C07D 417/04 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01);
U.S. Cl.
CPC ...
C07D 491/048 (2013.01); A61K 31/415 (2013.01); A61K 31/4164 (2013.01); A61K 31/421 (2013.01); A61K 31/4245 (2013.01); C07C 235/22 (2013.01); C07D 207/27 (2013.01); C07D 233/36 (2013.01); C07D 233/42 (2013.01); C07D 233/61 (2013.01); C07D 233/64 (2013.01); C07D 249/04 (2013.01); C07D 249/08 (2013.01); C07D 257/04 (2013.01); C07D 261/04 (2013.01); C07D 261/08 (2013.01); C07D 263/32 (2013.01); C07D 263/38 (2013.01); C07D 263/56 (2013.01); C07D 271/06 (2013.01); C07D 271/10 (2013.01); C07D 291/04 (2013.01); C07D 401/12 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 413/04 (2013.01); C07D 413/06 (2013.01); C07D 413/12 (2013.01); C07D 417/04 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01);
Abstract

The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.

Find Patent Forward Citations

Loading…